Zimmer Biomet Holdings, Inc. (ZBH) showed positive performance today, with the price at $88.57, up by $1.43 (1.64%) from the previous close of $87.14. Trading volume was robust at $1.30 million, marking a 57.06% increase compared to the average.
ZBH's latest quarterly earnings were reported on Monday, April 27th, with a consensus estimate EPS of 1.86.
The company offers a forward dividend yield of 1.08%, with a dividend per share of 24 cents for the most recent quarter and 96 cents trailing twelve months.
ZBH generated a free cash flow of $322.9 million, with operating cash flow at $359.2 million. Notably, common stock repurchases amounted to -$250.1 million.
Revenue stood at $2 billion, yielding a gross profit of $1.51 billion. The net income reported was $238.1 million, translating to an EPS of $1.22.
Key ratios include a gross profit margin of 72.39%, net profit margin of 11.41%, and a debt-equity ratio of 50.69.
The company holds total assets of $22.72 billion, with total liabilities at $7.98 billion, resulting in net debt of $7 billion.
This comprehensive overview provides insights into ZBH's financial standing and recent performance.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.